Neratinib (Breast cancer) Analysis and Forecasts to 2020


#28323

46pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Neratinib (Breast cancer) - Analysis and Forecasts to 2020 provides Neratinib sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US and EU5.
  • Analysis and review of Neratinib including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Neratinib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts from 2014-2020 for Neratinib in the US and EU5 markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 3
1.1 List of Tables 4
1.2 List of Figures 4


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Forecasts Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14


4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15


5 Predictive Biomarker in the Treatment of Breast Cancer 18


6 Treatment Options of Breast Cancer 20
6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27


7 Neratinib 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Factors Affecting Sales of Neratinib 30
7.4.1 Breast Cancer Market 30
7.4.2 Superior Efficacy 30
7.4.3 Only Irreversible Tyrosine Kinase Inhibition 30
7.4.4 Oral Administration 30
7.4.5 Approval in Japan 30
7.5 Drug Evaluation 30
7.5.1 Drug Risk Benefit Score 30
7.5.2 Intensity of Competition 31
7.6 Sales Forecasts 32
7.6.1 Target Patient Pool of Neratinib 32
7.6.2 Dosing 33
7.6.3 Market Penetration 33
7.6.4 Annual Cost of Therapy 33
7.6.5 Sales Projections of Neratinib 34


8 Breast Cancer Market: Appendix 42
8.1 Market Definitions 42
8.2 Abberiviations 42
8.3 Research Methodology 42
8.3.1 Coverage 42
8.3.2 Secondary Research 43
8.3.3 Forecasting 43
8.3.4 Number of Patients Approved to take the Drug 43
8.3.5 Net Penetration of Drug 44
8.3.6 Net Annual Dosing 45
8.3.7 Annual Cost of Therapy 45
8.3.8 Primary Research 45
8.3.9 Expert Panels 45
8.4 Contact Us 46
8.5 Disclaimer 46
8.6 Sources 46


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Drug Risk Benefit Score of Neratinib 31
Table 5: Neratinib, Breast Cancer, Global, Sales Forecasts ($m), 20142020 34
Table 6: Neratinib, Breast Cancer, The US, Sales Forecasts ($m), 20142020 35
Table 7: Neratinib, Breast Cancer, The UK, Sales Forecasts ($m), 20142020 36
Table 8: Neratinib, Breast Cancer, France, Sales Forecasts ($m), 20142020 37
Table 9: Neratinib, Breast Cancer, Germany, Sales Forecasts ($m), 20142020 38
Table 10: Neratinib, Breast Cancer, Italy, Sales Forecasts ($m), 20142020 39
Table 11: Neratinib, Breast Cancer, Spain, Sales Forecasts ($m), 20142020 40


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Global, 2010 5
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 7
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 8
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 9
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 9
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 10
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 10
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 12
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 12
Figure 12: Broad Classification of Breast Cancer, By Type 14
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 14
Figure 14: Classification of Invasive Breast Cancer, By Stages 15
Figure 15: Classification of Invasive Breast Cancer, By Treatment 15
Figure 16: Classification of Metastatic or Advanced Breast Cancer 15
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 16
Figure 18: Classification of Locally Advanced Breast Cancer 16
Figure 19: Metastatic Breast Cancer Classification 16
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 23: Treatment Options, DCIS Breast Cancer 19
Figure 24: Treatment Options, LCIS Breast Cancer 20
Figure 25: Treatment Options, Stages I, II and IIIA 20
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 33: Drug Model Diagram of Neratinib 31
Figure 34: Neratinib, Breast Cancer, Global, Sales Forecasts ($m), 20142020 33
Figure 35: Neratinib, Breast Cancer, The US, Sales Forecasts ($m), 20142020 34
Figure 36: Neratinib, Breast Cancer, The UK, Sales Forecasts ($m), 20142020 35
Figure 37: Neratinib, Breast Cancer, France, Sales Forecasts ($m), 20142020 36
Figure 38: Neratinib, Breast Cancer, Germany, Sales Forecasts ($m), 20142020 37
Figure 39: Neratinib, Breast Cancer, Italy, Sales Forecasts ($m), 20142020 38
Figure 40: Neratinib, Breast Cancer, Spain, Sales Forecasts ($m), 20142020 39
Figure 41: Neratinib, Breast Cancer, Sales Forecasts by Country ($m), 2020 40
Figure 42: Drug Model Diagram 43
Figure 43: Patients Approved for the Drug 44